Search

Your search keyword '"Yulia A. Palikova"' showing total 2 results
Start Over Author "Yulia A. Palikova" Journal biomedicines
2 results on '"Yulia A. Palikova"'

1. C-Terminal Region of Caveolin-3 Contains a Stretch of Amino Acid Residues Capable of Diminishing Symptoms of Experimental Autoimmune Encephalomyelitis but Not Rheumatoid Arthritis Modeled in Rats

Author

Alexey V. Danilkovich, Valery I. Turobov, Victor A. Palikov, Yulia A. Palikova, Anna O. Shepelyakovskaya, Evgeniy S. Mikhaylov, Gulsara A. Slashcheva, Tatiana E. Shadrina, Elvira R. Shaykhutdinova, Ekaterina A. Rasskazova, Elena A. Tukhovskaya, Oksana N. Khokhlova, Igor A. Dyachenko, Alina M. Ismailova, Dmitry V. Zinchenko, Elena V. Navolotskaya, Valery M. Lipkin, Arkady N. Murashev, and Igor. P. Udovichenko

Subjects
encephalomyelitis (EAE), collagen-induced arthritis (CIA), peptide, autoimmune disease, drugs, caveolin, Biology (General), QH301-705.5
Abstract

A short synthetic peptide from the C-terminal part of the caveolin-3 structure was tested for experimental autoimmune encephalomyelitis (EAE) treatment in rats. The structure–function similarity established between the novel synthetic peptide of pCav3 and the well-known immunomodulator immunocortin determined pCav3’s ability to reduce EAE symptoms in Dark Agouti (DA) rats injected with pCav3 (500 µg/kg). pCav3 was found to interfere with the proliferation of lymphocytes extracted from the LNs of DA rats primed with homogenate injection, with IC50 = 0.42 μM (2.35 mcg/mL). pCav3 affected EAE in a very similar manner as immunocortin. The high degree of homology between the amino acid sequences of pCav3 and immunocortin corresponded well with the therapeutic activities of both peptides, as demonstrated on EAE. The latter peptide, possessing a homologous structure to pCav3, was also tested on EAE to explore whether there were structural restrictions between these peptides implied by the MHC-involved cell machinery. Consequently, immunocortin was further examined with a different autoimmune disease model, collagen-induced arthritis (CIA), established in Sprague–Dawley rats. CIA was established using an intentionally different genetic platform than EAE. Based on the results, it was concluded that the effectiveness of pCav3 and immunocortin peptides in EAE rat model was almost identical, but differed in the rat model of rheumatoid arthritis; thus, efficacy may be sensitive to the MHC type of animals used to establish the autoimmune disease model.

Published
2023
Full Text
View/download PDF

2. TRPV1 Blocker HCRG21 Suppresses TNF-α Production and Prevents the Development of Edema and Hypersensitivity in Carrageenan-Induced Acute Local Inflammation

Author

A. A. Klimovich, Sergey A. Kozlov, V. A. Palikov, Igor A. Dyachenko, Yulia A. Palikova, Elena Leychenko, Olga Styshova, Irina Gladkikh, Margarita Monastyrnaya, and Oksana Sintsova

Subjects
0301 basic medicine, QH301-705.5, medicine.medical_treatment, Analgesic, TRPV1, Medicine (miscellaneous), Inflammation, Pharmacology, General Biochemistry, Genetics and Molecular Biology, TRPV1 inhibition, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Edema, medicine, Biology (General), Kunitz, Chemistry, Communication, analgesia, cytokines, Carrageenan, 030104 developmental biology, medicine.anatomical_structure, Cytokine, inflammation, Peripheral nervous system, TNF-α, carrageenan, Tumor necrosis factor alpha, medicine.symptom, hypersensitivity, edema, 030217 neurology & neurosurgery
Abstract

Currently the TRPV1 (transient receptor potential vanilloid type 1) channel is considered to be one of the main targets for pro-inflammatory mediators including TNF-α. Similarly, the inhibition of TRPV1 activity in the peripheral nervous system affects pro-inflammatory mediator production and enhances analgesia in total. In this study, the analgesic and anti-inflammatory effects of HCRG21, the first peptide blocker of TRPV1, were demonstrated in a mice model of carrageenan-induced paw edema. HCRG21 in doses of 0.1 and 1 mg/kg inhibited edema formation compared to the control, demonstrated complete edema disappearance in 24 h in a dose of 1 mg/kg, and effectively reduced the productionof TNF-α in both doses examined. ELISA analysis of blood taken 24 h after carrageenan administration showed a dramatic cytokine value decrease to 25 pg/mL by HCRG21 versus 100 pg/mL in the negative control group, which was less than the TNF-α level in the intact group (40 pg/mL). The HCRG21 demonstrated potent analgesic effects on the models of mechanical and thermal hyperalgesia in carrageenan-induced paw edema. The HCRG21 relief effect was comparable to that of indomethacin taken orally in a dose of 5 mg/kg, but was superior to this nonsteroidal anti-inflammatory drug (NSAID) in duration (which lasted 24 h) in the mechanical sensitivity experiment. The results confirm the existence of a close relationship between TRPV1 activity and TNF-α production once again, and prove the superior pharmacological potential of TRPV1 blockers and the HCRG21 peptide in particular.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results